The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), the enzyme which converts the amino acid arginine into nitric oxide (NO). ADMA has been identified as an important risk factor for cardiovascular diseases. Besides the role of ADMA in cardiovascular diseases, it also seems to be an important determinant in the development of critical illness, (multiple) organ failure, and the hepatorenal syndrome. ADMA is eliminated from the body by urinary excretion, but it is mainly metabolized by the dimethylarginine dimethylaminohydrolase (DDAH) enzymes that convert ADMA into citrulline and dimethylamine. DDAH is highly expressed in the liver, which makes the liver a key organ in the regulation of the plasma ADMA concentration. The prominent role of the liver in the elimination of ADMA and the consequences of impaired hepatic function on ADMA levels will be discussed in this article.

Get full access to this article

View all access options for this article.

References

Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999 ;43:521 -531.

Hinder F, Stubbe HD, Van Aken H, Waurick R, Booke M, Meyer J. Role of nitric oxide in sepsis-associated pulmonary edema. Am J Respir Crit Care Med. 1999;159:252 -257.

Wink DA, Cook JA, Pacelli R, Liebmann J, Krishna MC, Mitchell JB. Nitric oxide (NO) protects against cellular damage by reactive oxygen species. Toxicol Lett. 1995 ;82-83:221 -226.

Siegert A, Rosenberg C, Schmitt WD, Denkert C, Hauptmann S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. Br J Cancer. 2002 ;86:1310 -1315.

Forstermann U, Schmidt HH, Pollock JS, et al. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem Pharmacol. 1991 ;42:1849 -1857.

Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation. 2004 ;109:1813 -1818.

Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004 ;24:1023 -1030.

Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. 2006;26:2536 -2540.

Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001 ;88:1201 -1203.

10.

Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998 ;98:1842 -1847.

11.

Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med. 2005;10(suppl 1): S27-S33.

12.

Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr. 2006 ;26:203 -228.

13.

Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005;10(suppl 1): S73-S81.

14.

Nijveldt RJ, Teerlink T, Siroen MPC, van Lambalgen AA, Rauwerda JA, van Leeuwen PAM. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr. 2003 ;22:17 -22.

15.

Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001 ;358:2113 -2117.

16.

Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003 ;23:1455 -1459.

17.

Paik WK, Kim S. Protein methylase I. Purification and properties of the enzyme. J Biol Chem. 1968 ;243:2108 -2114.

18.

Lee HW, Kim S, Paik WK. S-adenosylmethionine: protein-arginine methyltransferase. Purification and mechanism of the enzyme. Biochemistry. 1977 ;16:78 -85.

19.

McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell. 2001 ;106:5 -8.

20.

Clarke S. Protein methylation. Curr Opin Cell Biol. 1993;5:977 -983.

21.

Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988 ;333:664 -666.

22.

Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992 ;20(suppl 12):S60 -S62.

23.

Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide. 1997 ;1:65 -73.

24.

Bulau P, Zakrzewicz D, Kitowska K, et al. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol. 2007;292:L18 -L24.

25.

Carnegie PR, Fellows FC, Symington GR. Urinary excretion of methylarginine in human disease. Metabolism. 1977 ;26:531 -537.

26.

Yudkoff M, Nissim I, Pereira G, Segal S. Urinary excretion of dimethylarginines in premature infants. Biochem Med. 1984 ;32:242 -251.

27.

Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem. 1989 ;264:10205 -10209.

28.

Leiper JM, Santa MJ, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343(pt 1): 209-214.

29.

Wang J, Sim AS, Wang XL, Wilcken DE. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci. 2006;63:2838 -2846.

30.

Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics. 2000 ;68:101 -105.

31.

Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 1999;43:542 -548.

32.

Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by NG-NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res. 2007 ;101:627 -635.

33.

Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003 ;108:3042 -3047.

34.

Hu T, Chouinard M, Cox AL, et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem. 2006;281:39831 -39838.

35.

Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res. 2002;90:764 -769.

36.

Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFα-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis. 2007 ;194:e1 -e8.

37.

Eid HM, Reims H, Arnesen H, Kjeldsen SE, Lyberg T, Seljeflot I. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism. 2007 ;56:464 -469.

38.

Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420 -1426.

39.

Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation. 2003 ;108:1575 -1580.

40.

Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P, Teerlink T. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. J Intern Med. 2006 ;259:199 -208.

41.

Teerlink T, Neele SJ, De Jong S, Netelenbos JC, Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond). 2003;105:67 -71.

42.

Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CD, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab. 2003 ;88:4221 -4226.

43.

Selley ML. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons. J Neurosci Res. 2004 ;77:90 -93.

44.

Jiang DJ, Jiang JL, Tan GS, Du YH, Xu KP, Li YJ. Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn Schmiedebergs Arch Pharmacol. 2003 ;367:600 -606.

45.

Saran R, Novak JE, Desai A, et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant. 2003 ;18:2415 -2420.

46.

Kostourou V, Robinson SP, Whitley GS, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res. 2003 ;63:4960 -4966.

47.

Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer. 2002 ;87:673 -680.

48.

Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun. 2003;308:984 -989.

49.

Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999 ;99:3092 -3095.

50.

Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002 ;106:987 -992.

51.

Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002 ;99:13527 -13532.

52.

Hattori Y, Kasai K, Gross SS. Cationic amino acid transporter gene expression in cultured vascular smooth muscle cells and in rats. Am J Physiol. 1999;276:H2020 -H2028.

53.

Kimoto M, Tsuji H, Ogawa T, Sasaoka K. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys. 1993;300:657 -662.

54.

Nijveldt RJ, Siroen MP, Teerlink T, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. Gut and liver handling of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in the rat under basal conditions and during endotoxemia. Liver Int. 2004 ;24:510 -518.

55.

Mittermayer F, Namiranian K, Pleiner J, Schaller G, Wolzt M. Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond). 2004 ;106:577 -581.

56.

Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology. 2005 ;41:559 -565.

57.

Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun. 1987 ;148:671 -677.

58.

Mookerjee RP, Dalton RN, Davies NA, et al. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl. 2007 ;13:400 -405.

59.

Lluch P, Torondel B, Medina P, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004 ;41:55 -59.

60.

Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frolich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2α in end-stage liver disease. Hepatology. 2003 ;38:1063 -1064.

61.

Laleman W, Omasta A, Van de Casteele M, et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology. 2005 ;42:1382 -1390.

62.

Zhong Z, Froh M, Wheeler MD, Smutney O, Lehmann TG, Thurman RG. Viral gene delivery of superoxide dismutase attenuates experimental cholestasis-induced liver fibrosis in the rat. Gene Ther. 2002;9:183 -191.

63.

Perez MJ, Macias RI, Duran C, Monte MJ, Gonzalez-Buitrago JM, Marin JJ. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol. 2005;43:324 -332.

64.

Sokol RJ, Straka MS, Dahl R, et al. Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids. Pediatr Res. 2001 ;49:519 -531.

65.

Vizzutti F, Romanelli RG, Arena U, et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest. 2007;37:509 -515.

66.

Mookerjee RP, Malaki M, Davies NA, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology. 2007 ;45:62 -71.

67.

Nijveldt RJ, Teerlink T, Siroen MP, et al. Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy. JPEN J Parenter Enteral Nutr. 2004 ;28:382 -387.

68.

Siroen MP, Warle MC, Teerlink T, et al. The transplanted liver graft is capable of clearing asymmetric dimethylarginine. Liver Transpl. 2004;10:1524 -1530.

69.

Martin-Sanz P, Olmedilla L, Dulin E, et al. Presence of methylated arginine derivatives in orthotopic human liver transplantation: relevance for liver function. Liver Transpl. 2003 ;9:40 -48.

70.

Lluch P, Mauricio MD, Vila JM, et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood). 2006;231:70 -75.

71.

Ng CK, Chan MH, Tai MH, Lam CW. Hepatorenal syndrome. Clin Biochem Rev. 2007 ;28:11 -17.

72.

Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GS. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet. 1993 ;342:242 -243.

73.

Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998;77:808 -813.

74.

Ellis J, Wennerholm UB, Bengtsson A, et al. Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand. 2001 ;80:602 -608.

75.

Holden DP, Fickling SA, Whitley GS, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 1998;178:551 -556.

76.

Lopez-Jaramillo P, Narvaez M, Calle A, et al. Cyclic guanosine 3',5' monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol. 1996 ;103:33 -38.

77.

Siroen MP, Teerlink T, Bolte AC, et al. No compensatory upregulation of placental dimethylarginine dimethylaminohydrolase activity in preeclampsia. Gynecol Obstet Invest. 2006 ;62:7 -13.

78.

Maas R, Boger RH, Schwedhelm E, et al. Plasma concentrations of asymmetric dimethylarginine (ADMA) in Colombian women with pre-eclampsia. JAMA. 2004;291:823 -824.

79.

Nijveldt RJ, Teerlink T, van der Hoven B, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr. 2003;22:23 -30.

80.

Nijveldt RJ, Teerlink T, van Leeuwen PAM. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr. 2003;22:99 -104.

81.

Nijveldt RJ, Siroen MP, Teerlink T, van Leeuwen PA. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure? J Nutr. 2004 ;134 (10 Suppl):2848S -2852S discussion 2853s.

82.

O'Dwyer MJ, Dempsey F, Crowley V, Kelleher DP, McManus R, Ryan T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care. 2006 ;10:R139 .

83.

Boger RH, Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol. 2001 ;41:79 -99.

84.

Pollock JS, Forstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A. 1991 ;88(10 Suppl):10480 -10484 discussion 2853s.

85.

Boger RH. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care. 2008;11:55 -61.

86.

Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr. 2004 ;134:2842S -2847S.

87.

Tsikas D, Boger RH, Sandmann J, Bode-Boger SM, Frolich JC. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett. 2000 ;478:1 -3.

88.

Tan B, Jiang DJ, Huang H, et al. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vascul Pharmacol. 2007 ;46:338 -345.

89.

Balabanli B, Erdamar H, Turkozkan N, Yaman H, Kurt Y. Effect of taurine on endotoxin-induced alterations in plasma asymmetric dimethylarginine, L-arginine and nitric oxide in guinea pigs. J Thromb Thrombolysis. 2007;24:53 -57.

90.

Fennessy FM, Moneley DS, Wang JH, Kelly CJ, Bouchier-Hayes DJ. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation. 2003 ;107:410 -415.

91.

Murakami S, Kondo Y, Sakurai T, Kitajima H, Nagate T. Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis. 2002 ;163:79 -87.

92.

van Hoorn EC, Middelaar-Voskuilen MC, van Limpt CJ, et al. Preoperative supplementation with a carbohydrate mixture decreases organ dysfunction-associated risk factors. Clin Nutr. 2005 ;24:114 -123.